about
Teriparatide for osteoporosis: importance of the full courseStudies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphataseFocal osteoporosis defects play a key role in hip fractureCortical thickness mapping to identify focal osteoporosis in patients with hip fractureThe use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Falls explain between-center differences in the incidence of limb fracture across Europe.The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis.Secondary osteoporosis: endocrine and metabolic causes of bone mass deterioration.Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.Osteoporosis in young adults: pathophysiology, diagnosis, and management.Strontium ranelate: in search for the mechanism of action.Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model.Geographic and other determinants of BMD change in European men and women at the hip and spine. a population-based study from the Network in Europe for Male Osteoporosis (NEMO).Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study.Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: the European Prospective Osteoporosis Study (EPOS).Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the "3rd Summit on Osteoporosis-CEE", November 2009, Budapest, Hungary.Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS).Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS).Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome.The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance.Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes.Isoenzyme of some dehydrogenases and nonspecific esterase in experimental virus hepatitis in mice.Alkaline phosphatase, lactate dehydrogenase and aspartate aminotransferase and their isoenzymes as indicators of the development of experimental virus hepatitis in mice.Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase.Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study.Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
P50
Q26768410-1C0E8115-C285-445B-82D1-48B7E05A22BEQ28266019-7F7E76BC-9F18-4483-9065-B6867BF75A0BQ28590202-ECBDC7AB-3663-4344-9BCE-EF66BF5E634BQ28728613-DB14DC77-2F7F-43B9-AB11-293B229D31FEQ34148384-1780F92F-F29E-4DE7-B4AD-DCD155814EE7Q34537434-2F0980FE-C23F-46F7-A0C6-055303793F31Q35047195-6D8F5614-7D01-4E79-AB4C-29F2D92888D1Q35099938-EC02C6B8-F447-4F18-B9EB-8F0210ACEC97Q35864492-7575725C-5C05-441F-B193-00B8D2D530A3Q37119404-802832D1-B4BF-4C73-8CC8-537281882AFCQ38017609-C4053B0E-2994-4146-9167-24BB58F7F3E7Q38127352-8BCF4204-7014-47AC-A150-103946AF083BQ38434012-9624F7C3-2137-499B-B216-11A8099F09CFQ38507656-D2B71FC1-2DCB-4E98-9CC5-7A231F33094AQ39762002-4064CD15-55E4-4AD7-918D-47F49B4C7A45Q40436890-CC2ED6AC-D0EA-405E-BCCF-375A3F91C713Q40563018-26B4DC91-7FCA-44C2-97A6-64C5631C3986Q41326206-25E94C1D-8945-4941-B025-49912D40FE4CQ41704724-1FBA0860-54B5-4F92-A003-9B537865A06BQ43172181-540DEC41-0DE7-47D1-A945-07F99421257CQ43744780-7133D184-8F8E-4CAB-A361-6E41A29001C2Q43782888-77488F38-3996-425E-88C9-33338B837553Q44254602-60E0AB46-2A62-4BC7-A03C-8AB975EC1818Q44309049-AA21CAF9-011F-4F9C-BF4B-003B2369D868Q44491862-9E1BB69F-018C-4AAE-91E0-71BCA324C7D3Q44614812-EEAE88A3-981D-44F6-8923-7EB9AC0E0DD1Q44791805-1798531D-D26C-4495-B884-FC0D144039C0Q44818645-C419F61F-1ADB-4F27-AD33-8FBF953C5F8DQ45797594-6B82A37E-46F0-48CF-BDF6-E60F388AFF29Q45811458-DB350BDA-D845-4394-AF0F-9008ED260650Q45812101-ED8F59CC-FF2C-458A-87CA-9FFBD97DDFF3Q46005783-DD66C036-D38F-4653-BD61-00B2640BEA92Q46065460-640FC098-6BCF-4643-837F-5405FE3230FAQ46159189-4477C6BE-D96C-4183-AFEA-D44930DB6A69Q46195599-EE963572-E60D-4809-A658-2DFD8FE508D2Q46276337-46E45F7C-E525-47A3-9EC2-D87D1EA4CB99Q46284190-47EC953E-D65C-4FC2-AB8C-C8D13BCF5AC5Q46286446-8BC0BB19-56A8-4643-B748-B941D87CA0FDQ46560179-C203063A-1E06-44FE-98E1-BE2876AF12A8Q46583319-724A594B-C98C-47AE-B209-531440A281F6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jan J. Stepan
@ast
Jan J. Stepan
@en
Jan J. Stepan
@es
Jan J. Stepan
@nl
Jan J. Stepan
@sl
type
label
Jan J. Stepan
@ast
Jan J. Stepan
@en
Jan J. Stepan
@es
Jan J. Stepan
@nl
Jan J. Stepan
@sl
altLabel
Jan J. Štěpán
@en
Stepán J
@en
prefLabel
Jan J. Stepan
@ast
Jan J. Stepan
@en
Jan J. Stepan
@es
Jan J. Stepan
@nl
Jan J. Stepan
@sl
P1053
A-7280-2013
P106
P1153
7102755080
P21
P2798
P31
P3829
P496
0000-0003-1541-8306